<DOC>
	<DOCNO>NCT01889758</DOCNO>
	<brief_summary>The study design compare steady-state pharmacokinetics Prograf ( Brand ) two disparate generic formulation ( Generic Hi Generic Lo ) fully replicate , 3-way cross-over study stable kidney ( n=36 ) liver transplant ( n=36 ) subject .</brief_summary>
	<brief_title>Pharmacokinetic Studies Tacrolimus Transplant Patients</brief_title>
	<detailed_description>To identify disparate tacrolimus generic drug formulation among currently approve United States . We conduct systematic dissolution test brand currently approve tacrolimus drug formulation use FDA-recommended dissolution method . We propose test compare 1mg capsule strength ( 3 production lots/ manufacturer ) . In addition , compare different formulation term potency , purity quality attribute . This work carry GMP-compliant facility The University Iowa Pharmaceuticals University Colorado . Based study two disparate generic tacrolimus formulation ( Generic Hi Generic Lo ) select compare Brand ( PrografR , Astellas , Deerfield , IL ) clinical trial . This open label , prospective , multicenter , randomize , replicate , six-period , three-sequence cross-over study compare steady state pharmacokinetics PrografR Generic Hi Generic Lo stable kidney liver transplant subject . The PK assessor blind assign treatment sequence formulation . The person analyze level analyze result blind formulation sequence . Each subject randomize one three sequence Generic Hi Generic Lo represent two generic B brand , Prograf . The blood sample collect C0 ( morning dose ) 20 , 40 , 60 ( 1hr ) , 80 , 100 , 120 ( 2hr ) , 140 , 160 , 180 ( 3hr ) minute , 4 , 5 , 6 , 8 12 hour dose formulation . Adherence monitor patient diary , pill count , MEMS cap . Safety efficacy parameter monitor weekly . This study carry full compliance rule Good Clinical Practice ( GCP ) include development electronic database monitoring plan . Resulting pharmacokinetic parameter analyze variety pharmacokinetic test narrower acceptance interval , individual scale average bioequivalence well population pharmacokinetics .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . ≥18 year old , male female 2 . Able participate willing give write informed consent comply study visit restriction . 3 . Subject receive primary secondary kidney liver transplant . 4 . Subject least 6 month posttransplant stable dose tacrolimus define physician , one tacrolimus trough level within physician define target range within past 6 month one additional trough level screen period within 30 % physician define target range . 5 . BMI great equal 19 less equal 40 . 6 . Ability perform daily finger stick provide blood sample 1 . Evidence acute rejection 2 . Subjects require dialysis within 6 month prior study entry 3 . Recipients multiple organ transplant 4 . Subjects test positive HBsAG HIV , recipient organ donor know HBsAG HIV positive . Virology screen time transplant . 5 . Hep C positive subject liver biopsy proven recurrent disease consider relevant physician oversight . 6 . Subjects severe medical condition require acute chronic treatment investigator 's opinion would interfere study participation 7 . History malignancy , treat untreated , past 2 year exception carcinoma situ excise basal cell carcinoma , hepatocellular carcinoma prior transplant . 8 . GFR ≤ 35 ml/min measure estimate use MDRD4 formula 9 . Subjects aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin ≥ 3 X upper limit normal ( ULN ) evidence severe liver disease 10 . Subjects white blood cell ( WBC ) count ≤2,000/ mm3 thrombocytopenia ( platelet count ≤ 75,000/ mm3 ) , absolute neutrophil count ≤ 1,500/ mm3 hemoglobin &lt; 8g/dL ) 11 . Subjects clinically significant infection , require therapy , , investigator 's opinion , would interfere objective study 12 . Other mental physical condition investigator 's opinion , consider clinically significant 13 . Presence intractable immunosuppressant complication side effect result dose adjustment tacrolimus 14 . Subjects expose investigational therapy within 30 day prior enrollment 5 halflives investigational product , whichever great . 15 . An anticipated change immunosuppressive regimen subject participation require protocol 16 . Subject severe GI disturbance diarrhea could interfere tacrolimus absorption 17 . Severe diabetic gastroparesis 18 . Initiation medication could interfere tacrolimus blood level , include OTC medication , herbal supplement , grapefruit grapefruit juice . 19 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive beta human chorionic gonadotrophin ( BhCG ) laboratory test ( &gt; 5 mIU/mL ) 20 . Women childbearing potential , defined woman physiologically capable become pregnant , unless 1. woman whose career , lifestyle , sexual orientation precludes intercourse male partner ; woman whose partner sterilize vasectomy 2. use highly effective method birth control ( i.e . one result less 1 % per year failure rate use consistently correctly , implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) ; periodic abstinence ( e.g . calendar , ovulation , symptothermal , postovulation method ) acceptable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>bioequivalence</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>kidney</keyword>
	<keyword>liver</keyword>
	<keyword>transplant</keyword>
</DOC>